Abstract
Significant advancements in the treatment of cancer have developed during the last four decades as a result of dedicated clinical and experimental efforts. Many of the therapeutic gains are related to discovery and development of more effective medicinal agents, technologic advancements, and an enhanced understanding of the fundamental chemical and biologic interactions involving the pathogenesis and pathophysiology of these heterogenous diseases. It is now possible to cure several types of malignancy and to achieve significant palliation in a variety of other tumors. Unfortunately, many of the more common types of neoplasms (e.g. carcinomas of the lung, breast, GI tract, and melanoma) are refractory to therapy with currently available agents. A most significant obstacle to address in the coming years is multiple drug resistance in which the cytotoxic action of pharmacologic agents is rendered ineffectual by a transmembrane pump in tumor cells (1–3). Early in this past decade, infection with the human immunodeficiency virus (HIV) has presented a major health problem because of the lethal nature of the disease, significant latent interval between infection and disease manifestation, fluctuating/ evolving epidemiologic patterns, and the lack of effective therapy. An important complication of pharmacologic agents that must be considered in the development of new therapeutic agents for the AIDS and neoplastic disorders are the immediate and long term clinical toxicities that frequently affect the quality of life (4). Because of the immediate and life-threatening nature of these diseases the untoward effects of these agents have been monitored and managed expectantly, since some toxicities can be lethal to the patient. Our primary research is directed towards generating new classes of pharmacologic agents possessing highly specific cytotoxicity for neoplastic cells, and cells that have incorporated the HIV genome. The major goals of developing such agents will be to cure these diseases which are currently refractory to therapy with minimal patient toxicity.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
In: Cancer: The Principles and Practice of Oncology. VT DeVita, S Heliman, SA Rosenberg (eds), Saunders, 1985.
Wittes RE: Current emphasis in the clinical drug development program of the National Cancer Institute. In: Cancer: The Principles and Practices of Oncology Supplement, Vol. I. VT DeVita, S Hellman, SA Rosenberg (eds), Saunders, 1987.
The Pharmacologic Basis of Cancer Treatment. BA Chabner (ed), Saunders, 1982.
Perry MC, Yarbro JW: Toxicity of Chemotherapy. Grune and Stratton, 1982.
Singh UC: QUEST (version 1.1), Scripps Clinic and Research Foundation,1987.
Singh UC, oilman PA: An approach to computing electrostatic charges for molecules. J. Comput. Chem. 5:129–145, 1984.
Frisch MJ, Binlley JS et al: Gaussain 86. Carnegie-Mellon Quantum Chemistry Publishing Unit, Pittsburgh, PA, 1984.
Hehre WJ, Radom L, V.R.Schleyer P, Pople: Ab Initio Molecular Orbital Theory. Wiley Publishing Co., 1986.
Singh UC, Weiner PK, Caldwell JW, Kollman PA: AMBER VERSION 3.0 (University of California — San Francisco), 1986.
Weiner SJ, Kollman PA, Case DA et al: A new force field for molecular mechanical simulation of nucleic acids and proteins. J. Amer. Chem. Soc. 106:765–784, 1984.
Singh UC, Brown FK, Bash P, Kollman PA: An approach to the application of free energy perturbation methods using molecular dynamics. J. Amer. Chem. Soc. 109:1607–1614, 1987.
Singh UC: Probing the salt bridge in the dihydrofolate reductase-methotrexate coordinate complex by using the coordinate coupled free energy perturbation method. Proc. Nat. Acad. Sci. 85:4280–4284, 1988.
Miller P, T'so POP: A new approach to chemotherapy based on molecular and nucleic acid chemistry: MATAGEN. Anti-Cancer Drug Design 2:117–128, 1987.
Hausheer FH, Singh UC, Colvin OM: Identification of local determinants of DNA interstrand crosslink formation by cyclophosphamide metabolites. Anti-Cancer Drug Design 4:281–294, 1989.
Palmer TC, Hausheer FH, Saxe JD: Applications of ray tracing in molecular graphics. J. Mol. Graphics 7:160–164, 1989.
Hausheer FH, Singh UC, Saxe JD et al: Enhanced binding of methylphosphonate modified oligodeoxynucleotides in triplestranded poly [dT] [dA] [dT] demonstrated by molecular dynamics. Proc. AACR 30:629, 1989.
Hausheer FH, Singh UC, Saxe JD et al: Can oligonucleotide methyphosphonates form a stable triplet with a DNA duplex? Anti-Cancer Drug Design 5:159–167, 1990.
Palmer TC, Hausheer FH, Saxe JD: Context-free spheres: A new method for rapid CPK image generation. J. Mol. Graphics 6:149–154, 1988.
Hausheer FH, Singh UC, Palmer TC, Saxe JD: Dynamic properties and electrostatic potential surface of neutral DNA heteropolymers. Journal of American Chemical Society (in press) 1990.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media New York
About this chapter
Cite this chapter
Hausheer, F.H., Singh, U.C., Saxe, J.D., Weis, A.L. (1992). Supercomputer Aided Drug Design: Application in Oncology and AIDS. In: Valeriote, F.A., Corbett, T.H., Baker, L.H. (eds) Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development. Developments in Oncology, vol 68. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3492-1_12
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3492-1_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6548-8
Online ISBN: 978-1-4615-3492-1
eBook Packages: Springer Book Archive